Antabio CEO Says M&A Is His ‘Exit Strategy’
‘Broken’ AMR Model Leaves Antibiotics Maker No Other Choice
Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.
You may also be interested in...
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.